Investing.com - Biohaven Pharma reported on Wednesday third quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Biohaven Pharma announced earnings per share of $-1.25 on revenue of $0.00. Analysts polled by Investing.com EPS of $-2.11 on revenue of $251.19M.
Biohaven Pharma 's are down 0.45% and is trading at $14.98 , still down 90.11% from its 52 week high of $151.50 set on Monday, September 19, 2022.
Biohaven Pharma shares lost 3.79% to trade at $14.98 in intra-day trade the report.
Biohaven Pharma follows other major Healthcare sector earnings this month
Biohaven Pharma's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar